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ABSTRACT

OBJECTIVE
The objective of this selective EBM review is to determine whether or not the use of Apixaban
or Enoxaparin is more effective in the prophylaxis of venous thromboembolism post-orthopedic
surgery.
STUDY DESIGN
Review of three English language randomized, double-blind, placebo-controlled clinical trials
from 2009-2010.
DATA SOURCES
Randomized, double-blind placebo controlled, clinical trials comparing the effectiveness of
Apixaban and Enoxaparin in the prophylaxis of Venous Thromboembolism (VTE) postorthopedic surgery were found using PubMed, the Cochrane Database of Randomized Controlled
Trials, and the Cochrane Databases of Systematic Reviews.
OUTCOMED MEASURED
Development of venous thromboembolism (VTE) post-orthopedic surgery including Total Knee
Replacement (TKR) and Total Hip Replacement (THR) compared to preoperative baseline was
measured using four different modes of detection: Bilateral Venography, Ventilation Perfusion
Scan, Spiral CT, Pulmonary Angiography, and bleeding during the treatment phase.
RESULTS
ADVANCE-1 (Apixaban Dose Orally vs. Anticoagulation with Enoxaparin) compared the
efficacy of 2.5mg of Apixaban twice daily with that of Enoxaparin 30mg subcutaneous dosing
twice daily post-TKR. Both regimens were initiated 12-24 hrs post surgery. No clear VTE rate
reduction was evident with either drug, both exhibited similar results of 8.8% Enoxaparin, 9.0%
Apixaban. However, reduced bleeding with Apixaban was observed. ADVANCE-2 focused on
the two interventions, Apixaban 2.5mg twice daily initiated 12-24 hrs post surgery in comparison
to Enoxaparin regimen of 40 mg subcutaneously 12 hrs prior and continued 10-14 days postTKR. It was observed that Apixaban was superior to Enoxaparin post-TKR with a 9.3% relative
reduction rate in VTE formation and 1% decline in bleeding episode. ADVANCE-3 evaluated
the efficacy of Apixaban and Enoxaparin post-THR at the same dosage and administration as
ADVANCE-2 TKR trial, however the treatment regimen was continued 35 days post-THR
surgery. ADVANCE-3 trial concluded Apixaban was far more effective at VTE rate reduction
with 1.4% compared with 3.9% of Enoxaparin use.
CONCLUSIONS
The use of Apixaban 2.5 mg orally twice daily is an appropriate, safe and effective
alternative to the traditional Enoxaparin for thromboprophylaxis post-orthopedic surgery.
KEY WORDS
Venous Thromboembolism (VTE), Thromboprophylaxis Post-Orthopedic Surgery, Enoxaparin,
Apixaban
INTRODUCTION
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Venous Thromboembolism (VTE) is a major source of morbidity and mortality
worldwide. It encompasses both Deep Venous Thrombosis (DVT) and Pulmonary Embolism.1
This highly preventable medical condition affects over 1 million people each year and accounts
for approximately 300,000 deaths/year.2
The aging population in the United States is on the rise with the influx of the baby
boomer generation, which will yield a growth of degenerative diseases. As this population soars,
it is of significant relevance to not only the patient but to the primary care giver whose role will
be to ensure the safety of managing the pharmacotherapy and provide proper patient education.
As we age our joints become subject to deleterious effects of certain pathologic diseases
such as Osteoarthritis and Rheumatoid Arthritis, which warrant the need for joint replacement.3,4
By 2030, there will be an estimated 174% increase in total hip replacements and 673% increase
in knee replacements.3 One of the major complications of orthopedic surgery is venous
thromboembolism. The economic burden of VTE in the United States incurs high health care
costs of approximately $1.5 billion per year. Initial treatment and management of a single VTE
event is approximately $3000-$9500. Total cost of VTE treatment over 3 months is $5000, six
months, $10,000, and one year is estimated at $33,000.5-7 The exorbitant cost can be attributed to
long-term complications including Chronic Thromboembolic Pulmonary Hypertension (CTPH),
Post-Thrombotic Syndrome (PTS), reoccurrence and follow-up treatment necessary when on
anticoagulant therapy. Patients with VTE spend ten times as long in the Intensive Care Unit and
more than twice as long hospitalized as those without a VTE.5,7
Venous thromboembolism is the third most common cardiovascular illness after acute
coronary syndrome and stroke. Venous thromboembolism results from a combination of factors
that contribute to the formation of a clot, hypercoaguable states, hereditary and acquired risk
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factors, surgery, trauma, venous stasis, and vessel wall damage. Venous thrombi are formed from

red blood cells, platelets, and leukocytes that are bound together by fibrin, where it adheres to a
site of damaged vessel. Deep Venous Thrombosis is the most common form of VTE and forms
in the distal calf veins where it propagates to the proximal veins and breaks free forming
potentially lethal emboli to the pulmonary system resulting in a pulmonary embolus.9 Therefore,
patients undergoing orthopedic joint replacement surgery including total knee and hip
replacements are at high risk of venous thromboembolism.10
There is significant armamentarium of anticoagulant therapy used in the treatment and
prophylaxis of VTE, which includes: Low-Dose Unfractionated Heparin, Low-Molecular Weight
Heparin (Enoxaparin, Dalteparin), Factor Xa Inhibitor (Fondaparinux), and Vitamin K agonists
(Warfarin). The benefit to the use of Warfarin has considerably decreased postoperative VTE,
however there are several impediments to its use. Patient compliance is of great concern; there
are several drug and food interactions, rigorous monitoring, and first and foremost the risk of
bleeding during therapy. Low-Molecular Weight Heparins (LMWH) such as Enoxaparin has
been the FDA approved therapy for prophylaxis of VTE. This drug class negates the need for
constant monitoring, however it is administered subcutaneously, which may require home health
assistance or significant patient compliance and education.11
Current pharmacologic treatment for prevention of VTE postoperative provides effective
prophylaxis short-term, however a significant risk for VTE remains in those patients with THR
and TKR. It has documented that subclinical venous thrombosis occurs in 15-20% of THR and
30-40% of patient who have undergone TKR.12
Optimal anticoagulant prophylaxis of VTE post-orthopedic surgery would prove to be a
therapeutic agent that does not require monitoring, one that has easy patient compliance, limited
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adverse reactions (i.e. bleeding) and have an antidote. Several new anticoagulants are currently
being investigated in the prevention and treatment of VTE in orthopedic patients, one of which is
Apixaban, a Factor Xa Inhibitor. This oral drug formulation has multiple routes for elimination,
reaches peak levels after 3 hrs of dosing, a half-life estimated between 9-14 hrs., and no
monitoring parameters.13 The following randomized, double blind clinical trials, and placebocontrolled studies to be examined have compared Apixaban to Enoxaparin for the prophylaxis of
VTE after THR and TKR.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not the use of Apixaban
or Enoxaparin is more effective in the prophylaxis of venous thromboembolism post-orthopedic
surgery.
METHODS
The criteria used for the selection of the three studies included: 1) the population patients
involved in the study were females ages 60 and older post-orthopedic surgery THR and TKR, 2)
the intervention measured was Apixaban, 2.5mg dose twice daily), 3) the comparison group
evaluated at two different doses of Enoxaparin, 30mg and 40mg, twice and once daily,
respectively, 4) the outcomes addressed were VTE prophylaxis 10-14 days post-TKR and THR,
and 35 days post-THR. The three chosen studies to be analyzed: 1) ADVANCE-1 comparing
Apixaban (2.5mg) with Enoxaparin (30mg) post-TKR, 2) ADVANCE-2 comparing Apixaban
(2.5mg) with Enoxaparin (40mg) post-TKR, and THR comparing Apixaban (2.5mg) with
Enoxaparin (40mg) post-THR.
Randomized, double-blind placebo controlled, clinical trials comparing the effectiveness
of Apixaban and Enoxaparin in the prophylaxis of Venous Thromboembolism (VTE) post-
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orthopedic surgery were found by the author using PubMed, the Cochrane Database of

Randomized Controlled Trials, and the Cochrane Databases of Systematic Reviews from 20092010.

Key words used: Venous Thromboembolism (VTE), Thromboprophylaxis Post-

Orthopedic Surgery, Enoxaparin, and Apixaban. All trials were published in peer-reviewed
journals in the English language, were selected based on the importance of outcomes to the
patient (Patient Oriented Evidence that Matters, POEMS). Inclusion criteria consisted of studies
that focused on treatment and prophylaxis with Apixaban, that were randomized placebocontrolled, double blind clinical trials that focused on patient oriented outcomes. Exclusion
criteria included active bleeding or contraindication to anticoagulant treatment.
The statistics used in the study included p-values with confidence intervals (CI), numbers
needed to treat (NNT), numbers needed to harm (NNH), relative risk (RR), relative risk
reduction (RRR), relative risk increase (RRI) and absolute risk increase (ARI). The
demographics and characteristics included in the studies are shown in Table 1.
OUTCOMES MEASURED
The primary outcomes measured by the three studies analyzed was the presence or
absence of developing a VTE (DVT and PE) post-TKR and THR. Several means were used to
access this outcome at the end of the anticoagulation treatment phase in all studies: bilateral
venography to access for DVT and if pulmonary embolus was suspected then spiral CT or
pulmonary angiography studies were conducted. ADVANCE-1 study evaluated the efficacy of
two drugs, Apixaban 2.5 mg or Enoxaparin 30 mg subcutaneously, beginning 12-24 hrs post-
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TABLE 1. Demographics and Characteristics of the Included Studies
STUDY
Advance
1
Lassen, et
al., 2010

Advance
2
Lassen, et
al., 2009

Advance
3
Lassen, et
al., 2010

TYPE

#
PTS
3057

AGE
(yrs)
Age>66

Inclusion
Criteria
•Female
•Elective
unilateral
TKR or same
day bilateral
TKR

RCT
3195
(doubleblind
control
study

Age>65

•Female
•Elective
unilateral or
bilateral TKR
•Or revision
surgery of a
previous joint
replacement

RCT
(double
blind
control
study

Age>60

Female
Same criteria as
Lassen et al 2010
•Elective
THR
•Or revision
surgery of a
previous joint
replacement

RCT
(doubleblind,
phase
III
study)

5407

Exclusion
Criteria
•Active Bleeding
•Requirement of
ongoing prophylaxis
with anticoagulant
therapy
• Uncontrolled HTN,
↓Renal Function,
Heparin Allergy,
Thrombocytopenia,
Active Hepatobiliary
Disease, Allergy to
Radiocontrast Dye
•Same criteria as
Lassen
et al 2010

W
/D
0

Intervention

0

•Apixaban 2.5 mg PO
BID + inj. of placebo
Enoxaparin once
daily, 12-24 hrs post
surgery & continued
10-14 days
• Enoxaparin, 40mg
SC inj. once daily +
placebo tablets, 12-24
hrs post surgery and
continued 10-14 days

0

Apixaban 2.5 mg PO
BID + inj. of placebo
Enoxaparin once
daily, starting 12-24
hrs post surgery
x 35 days
• Enoxaparin, 40mg
SC inj. once daily +
placebo tablets,
starting 12 hrs prior to
surgery x 35 days

• Apixaban 2.5mg
twice orally +
Enoxaparin placebo
inj., once daily, 1224hrs post surgery &
continue10-14 days
• Enoxaparin 30mg
SC twice daily, 12 hrs
prior to surgery &
continued 10-14 days.
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TKR surgery and continued for 10-14 days. Patients were followed-up at days 30 and 60, after
cessation of anticoagulation.12
ADVANCE-2, phase 3, study focused on Apixaban 2.5 mg twice/daily beginning 12-24
hrs post-wound closure and Enoxaparin 40 mg subcutaneously once daily injections starting 12
hrs prior to TKR surgery. All medications were continued for 10-14 days and were evaluated at
days 30 and 60 post-TKR.14

Lassen et al. conducted the ADVANCE-3 trial, which measured VTE formation postTHR. Apixaban 2.5 mg twice/daily and Enoxaparin 40 mg subcutaneously once/daily, were
used starting 12 hrs prior to THR surgery. Treatment regimens were continued for 35 days.
Patients were followed for an additional 65-95 days post-THR.15
All three studies included adverse affects to treatment, which included major and minor
bleeding episodes that occurred during the treatment phase and within 2 days after stopping the
medication, elevations in aminotransferase, bilirubin levels, stroke, and myocardial infarction
were also analyzed during the treatment phase and follow-up periods. In each phase 3 trial the
adverse affects were recorded for each treatment group.12, 14,15
RESULTS
ADVANCE-1 study evaluated 3195 female patients ages 65 years who underwent
randomization for TKR.

1599 were treated with Apixaban 2.5 mg orally twice/daily plus

placebo-Enoxaparin injections starting 12-24 hrs post-TKR. 1596 patients were administered 30
mg subcutaneous Enoxaparin twice/daily. Both medications were started 12-24 hrs postoperative
and continued for 14 days. Patients were followed 60 days after cessation of anticoagulation.12 It
was observed that VTE developed in 9.0% patients in the Apixaban group with a 95%CI, 0.781.32 and ρ=0.06 in comparison with the Enoxaparin group 8.8% with a 95% CI, -2.22-2.44 and

Bohensky, VTE Prophylaxis Post-TKR & THR 9

ρ<0.001.12 The percentage of VTE formation with the use of Apixaban was not significantly
different from the Enoxaparin therapy post-TKR.12
ADVANCE-2, phase 3 study focused on females ages 66-67 years undergoing TKR.
3057 patients were selected for the study. 1528 females were randomized to the Apixaban group,
where 976 were selected completed the study through the follow-up period. N=552 were
excluded because they either did not undergo venography or had venograms that could not be
interpreted. 976 patients received Apixaban 2.5 mg twice/daily plus beginning 12-24 hrs postwound closure plus placebo-Enoxaparin injections beginning 12 hrs prior to TKR surgery. 1529
females were randomized for the Enoxaparin group. Of the 1529 females, N=552 were excluded
did not undergo venography or had uninterpretable results. 997 patients completed the trial,
receiving Enoxaparin 40 mg subcutaneously once/daily injections starting 12 hrs prior to TKR
surgery plus placebo-Apixaban tablets twice/daily starting 12-24 hrs post-wound closure. All
medications were continued for 10-14 days and patients were evaluated at days 30 and 60 postTKR.14 Apixaban was found to be superior to Enoxaparin VTE events at 15% and 24%
respectively, with a 95% CI, 0.51-0.74, ρ<0.0001. Furthermore, ADVANCE-2 confirmed VTE
results with 75% of the suboptimum venograms able to be interpreted. In addition, 78% of the
initial study population for the allocation of Apixaban and Enoxaparin groups could be assessed
for VTE. The ADVANCE-3, phase 3 study, evaluated 5407 females, ages 60 years, undergoing
THR. 2708 females were randomized to receive Apixaban. N=759 were excluded due to noncompliance with venography or uninterruptible venograms. 1949 patients received Apixaban 2.5
mg twice/daily plus placebo Enoxaparin beginning 12-24 hrs post-wound closure. 2699 patients
were randomized into the Enoxaparin treatment group, n=782 patients were excluded from the
study due to aforementioned exclusion criteria in the Apixaban group. 1917 females were treated
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with 40 mg subcutaneously once daily starting 12 hrs prior to THR surgery plus placeboApixaban 12-24 hrs post-THR. Treatment regimens were continued for 35 days. Patients were
followed for an additional 65-95 days post-THR.15 It was observed that females undergoing hip
replacement treated with Apixaban had a reduced rate of VTE formation of 1.9% and 3.9% of
Enoxaparin. 95% CI, 0.22 to 0.54, 95% CI, 0.51-0.74, ρ<0.001. Again, Apixaban was superior to
that of Enoxaparin at the dosage parameters set for this study.15
In the three studies analyzed, the participants involved did experience some adverse side
effects. This data was reported as the number of patients that experienced adverse side effects of
major bleeding defined as clinically overt bleeding, hemoglobin drop of greater than 20g/L in 24
hrs, bleeding at a critical site and transfusion of two or more units of packed red blood cells,
minor bleeding episodes, stroke, myocardial infarction, elevation in aminotransferase and
billirubin levels to as a result of the anticoagulant medication as represented in Table 2.12, 14,15
In the ADVANCE-1 trial the most common adverse side effect was major bleeding event.
Apixaban was associated with a lower risk of bleeding, 0.7%, in comparison to 1.4% with
Enoxaparin as demonstrated in Table 2. Least common adverse effects observed in both groups
TABLE 2. Adverse Side Effects Profile
ADVANCE-1 (N,%) ADVANCE-2 (N,%) ADVANCE-3 (N%)
Major Bleeding
Minor Bleeding
MI
Stroke
↑Aminotransferase
↑Bilirubin

Apixa
11(0.7)
39(2.4)
2(0.1)
0
18(1.1)
2(0.1)

Enoxa
22(1.4)
40(2.5)
5(0.3)
2(0.1)
27(1.7)
8(0.5)

Apixa
9(0.6)
51(3.4)
1(<1)
2(<1)
25(2)
15(<1)

Enoxa
14(0.9)
54(3.6
1(<1)
0
23(2)
8(<1)

Apixa
22(0.8)
184(6.9)
9(0.3)
1(0.1)
37(1.4)
27(1)

Enoxa
18(0.7)
200(7.5)
4(0.2)
5(0.2)
46(1.8)
13(0.5)

Apixa=Apixaban, Enoxa=Enoxaparin, MI=Myocardial Infarction

were elevations in aminotransferase and billirubin levels, indicating a low risk for hepatotoxicity
with use of Apixaban.12 However, a total of 8 patients incurred a thromboembolic event in both
groups, and 9 patients died during the study period. The ADVANCE-2 study observed no
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difference in major bleeding episodes between the two groups. Other adverse side effects were
MI, stroke, nausea, vomiting and constipation, which were found to be similar between the two
groups in each conducted study (see TABLE 2). Four patients died during the study period.14 The
ADVANCE-3 trial also noted no elevated risk of bleeding episodes between the two groups as
well as thromboembolic events.
Table 3 shows the adverse event rates in the control group (CER, control event rate) and
the experimental event rate (EER). The CER depicts those who received Enoxaparin and
developed VTE and the EER was determined as those who were administered Apixaban who
experienced a VTE. The ADVANCE-1 study observed a negative relative risk (RRI) that depicts
that an adverse reaction is less likely to occur in the experimental verses the control group. The
absolute risk increase (ARI) demonstrates the difference in risk between both the control and
experimental groups. In the ADVANCE-3 study the ARI is 0.2%, which means there is an
absolute relative increase in bleeding with the use of Apixaban. Number Needed to Harm
(NNH) was calculated to determine the number of people exposed to treatment to cause one
person harm. In the ADVANCE-2 trial, for every 100 patients treated one person will experience
an adverse event such as an MI, stroke, major/minor bleeding, or elevation in bilirubin or
aminotransferase, compared to control.
TABLE 3 Analysis of Outcomes and Numbers Needed to Harm in Patients
Prophylaxed with Apixaban and Enoxaparin Post-Orthopedic Surgery
STUDY

ADVANCE-1
ADVANCE-2
ADVANCE-3

# PATIENTS
COMPLETED
STUDY
3195
3057
5407

CER

EER

RRI

ARI

NNH

4.3%
4%
4.8%

2.9%
5%
5%

-33.5%
25%
4.2%

-1.4%
1%
0.2%

72
100
5
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Table 4 depicts the amount of patients that needed to be treated to prevent adverse

effects. The ADVANCE-2 study had the most significant data demonstrating that in order to
prevent one bad outcome from occurring in this study, 12 patients would need to be
treated to prevent a harm of one VTE post-TKR.

TABLE 4 Analysis of Outcomes and Numbers Needed to Treat in Patients Prophylaxed
with Apixaban and Enoxaparin Post-Orthopedic Surgery

STUDY

ADVANCE-1
ADVANCE-2
ADVANCE-3
DISCUSSION

# PATIENTS
COMPLETED
STUDY
3195
3057
5407

CER

EER

RRR

ARR

NNT

8.8%
24%
1.4%

9%
15%
3.9%

2.27%
37.5%
1.78%

0.2%
9%
2.5%

5
12
1

Two of the three studies addressed in this paper demonstrate that Apixaban

administered 2.5 mg orally twice/daily is superior to current standard therapy,
Enoxaparin, 40mg subcutaneously once/daily in the prevention of VTE post-orthopedic
surgery.

14,15

This novel drug has many additional benefits compared to the standard

therapy such as: no routine monitoring, oral dosing, short half-life, and limited food

interactions, which may be attractive for patient compliance. One of the major risks of postorthopedic surgery is bleeding, as a safety measure this is of relative importance. It has
been shown that treatment with Apixaban is associated with lower rates of bleeding episodes

than traditional therapy, 4.8% and 5.0% of patients in the Apixaban and Enoxaparin groups,
respectively (P=0.72).15 However, there is no reversal for this agent, drug interaction data is

not available and foremost Apixaban has only been recently FDA approved for the

treatment of stroke and systemic emboli in patients suffering from atrial fibrillation in the
US.16 Apixaban (Eliquis®) is currently being used in Europe as a prophylactic measures

against VTE post knee and hip surgery.17
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The present analysis has several limitations that could have contributed to the

results. Lack of information regarding the patient’s health status or co-morbidities prior to

surgery, such as total cholesterol levels, organ function, cancer, diabetes, and physical
therapy sessions post surgery which all can contribute to the recovery phase.

All three studies also focused primarily on women. It has been documented that

arthritis affects an estimated 46.4 million adults in the U.S., of whom 61 percent (28.3 million)
are women.18 However, degenerative joint disease, which is a leading cause of joint
replacement surgery, affects both sexes. Although, the men make up a smaller percentage of
the arthritic population, they should be accounted for in future studies when evaluating VTE
prophylaxis post orthopedic surgery.
CONCLUSION
Apixaban offers a safe and effective alternative for the prophylaxis of VTE postorthopedic surgery. This was proved by both the ADVANCE-2 and ADVANCE-3 trials, where
the administration of 2.5 mg Apixaban orally twice/daily led to significant risk reduction of
VTE, without increased incidence of bleeding events.14,15
The ADVANCE-1 study showed Apixaban was inferior to Enoxaparin for VTE
prevention; however, it did demonstrate lower major bleeding rates, proving Apixaban may be
an attractive option for orthopedic surgeons concerned with bleeding post-TKR and THR, which
can predispose the patient to infections that can lead to destruction of the prosthesis.12 In
summary, the use of Apixaban in post orthopedic surgery is supported by lower rates of VTE and
no further increase in bleeding episodes. Its relative ease of use, rapid onset of action and
pharmacokinetic properties prove to be a novel anticoagulant alternative at the forefront of
clinical medicine that will transform patient care and compliance.
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